ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0392

Evaluation for the Presence of Antibodies to Malondialdehyde-Acetaldehyde Adduct in Juvenile Idiopathic Arthritis and Its Subtypes

Geoffrey Thiele1, Panteha Hayati Rezvan2, Michal Cidon2, Carlos Hunter3, Michael Duryee3, Ted Mikuls3 and Geoffrey Thiele3, 1Children's Hospital of Los Angeles, Omaha, NE, 2Children's Hospital of Los Angeles, Los Angeles, CA, 3University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2024

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), Biomarkers, Juvenile idiopathic arthritis, Measurement, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Studies of rheumatoid arthritis (RA) have shown that malondialdehyde-acetaldehyde (MAA) protein adducts and anti-MAA immune responses play a pathogenic role in disease progression. Expression of MAA-modified proteins are increased in RA synovium and circulating anti-MAA antibodies are higher in adults with RA than in controls including patients with other rheumatologic conditions.1 Despite marked similarities in disease pathogenesis, the role of MAA and anti-MAA antibodies have not been evaluated in Juvenile Idiopathic Arthritis (JIA). The objective of this study was to compare serum levels of anti-MAA antibody in patients with JIA to levels in controls and to identify any potential factors in JIA associated with anti-MAA expression. We tested the hypothesis that anti-MAA antibodies would be higher in JIA and, among those with JIA, highest in children with polyarticular disease as well as those who are CCP or RF positive.

Methods: Serum samples were obtained from children diagnosed with all subtypes of JIA (except for systemic JIA) from a single pediatric medical center. Serum IgM, IgG, and IgA anti-MAA antibodies were measured by ELISA. Through chart review, demographic information as well as ANA, RF, CCP, and HLA-B27 status was determined. In initial analyses, anti-MAA antibody concentrations were compared with values measured in a cohort of unmatched healthy controls without JIA using a Student’s t-test. Anti-MAA antibody levels were compared across six JIA subtypes using Kruskal-Wallis tests. We further compared patients’ characteristics and anti-MAA antibody levels between those with positive and negative biomarkers using chi-square or Fisher’s exact tests for categorical variables and Wilcoxon rank-sum tests for continuous variables. Analyses were performed in Stata MP Release 18.2

Results: We studied 99 JIA participants with a mean age at visit of 15 years, mean age at JIA diagnosis of 8.7 years, 72.6% Hispanic, 70.7% female, 49% ANA positive, 30.4% RF positive, 33.3% CCP positive, and 16.4% HLA-B27 positive (Table 1).  IgM, IgG and IgA anti-MAA antibody levels were higher in JIA patients (n=99) compared to previously obtained group of unmatched, healthy controls (n=18; p≤0.0014) (Figure 1). Among those with JIA, there were no significant differences in levels of anti-MAA antibodies by arthritis subtype, ANA, RF, CCP or HLA-B27 status (Table 2).

Conclusion: This study showed that humoral immunity to MAA is increased in the context of JIA, with similar levels of expression observed across JIA subtypes and by other biomarkers commonly assessed in JIA.  These results support further research using large patient samples to determine diagnostic as well as prognostic value of anti-MAA antibodies in JIA.  Significant findings could further open the door for additional MAA studies in the realm of pediatrics, as it has also been shown to be positive in other autoimmune conditions such as pediatric IBD and lupus in adults.

Supporting image 1

Table 1. Demographics and Clinical Information (n=99)

Supporting image 2

Figure 1. Anti-MAA Antibodies in JIA Patients and Healthy Cohort

Supporting image 3

Table 2. Anti-MAA Antibodies by Patient Characteristics (n=99)


Disclosures: G. Thiele: None; P. Hayati Rezvan: None; M. Cidon: None; C. Hunter: None; M. Duryee: None; T. Mikuls: Elsevier, 9, Horizon Therapeutics, 2, 5, Pfizer, 2, Sanofi, 2, UCB Pharma, 2, Wolters Kluwer Health (UpToDate), 9; G. Thiele: None.

To cite this abstract in AMA style:

Thiele G, Hayati Rezvan P, Cidon M, Hunter C, Duryee M, Mikuls T, Thiele G. Evaluation for the Presence of Antibodies to Malondialdehyde-Acetaldehyde Adduct in Juvenile Idiopathic Arthritis and Its Subtypes [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/evaluation-for-the-presence-of-antibodies-to-malondialdehyde-acetaldehyde-adduct-in-juvenile-idiopathic-arthritis-and-its-subtypes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-for-the-presence-of-antibodies-to-malondialdehyde-acetaldehyde-adduct-in-juvenile-idiopathic-arthritis-and-its-subtypes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology